Xenon Pharmaceuticals Inc (NASDAQ:XENE) Director Frank A. Holler sold 5,069 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $9.32, for a total value of $47,243.08. Following the completion of the sale, the director now owns 136,129 shares in the company, valued at approximately $1,268,722.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Xenon Pharmaceuticals stock traded up $0.20 during midday trading on Friday, hitting $8.35. The company had a trading volume of 56,526 shares, compared to its average volume of 59,688. The company has a debt-to-equity ratio of 0.18, a quick ratio of 11.07 and a current ratio of 11.07. The stock has a market capitalization of $209.04 million, a P/E ratio of -6.28 and a beta of 1.32. The company has a 50 day moving average of $9.10 and a 200 day moving average of $9.47. Xenon Pharmaceuticals Inc has a 52-week low of $5.41 and a 52-week high of $11.40.
Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09. Equities research analysts forecast that Xenon Pharmaceuticals Inc will post -1.88 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Morgan Stanley boosted its stake in Xenon Pharmaceuticals by 25.3% during the 2nd quarter. Morgan Stanley now owns 6,148 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,241 shares during the last quarter. United Services Automobile Association boosted its stake in Xenon Pharmaceuticals by 2.4% during the 2nd quarter. United Services Automobile Association now owns 101,039 shares of the biopharmaceutical company’s stock valued at $996,000 after purchasing an additional 2,400 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Xenon Pharmaceuticals by 0.7% during the 2nd quarter. Renaissance Technologies LLC now owns 475,500 shares of the biopharmaceutical company’s stock valued at $4,688,000 after purchasing an additional 3,200 shares during the last quarter. Royal Bank of Canada boosted its stake in Xenon Pharmaceuticals by 5.8% during the 2nd quarter. Royal Bank of Canada now owns 60,340 shares of the biopharmaceutical company’s stock valued at $595,000 after purchasing an additional 3,302 shares during the last quarter. Finally, Knott David M boosted its stake in Xenon Pharmaceuticals by 3.5% during the 1st quarter. Knott David M now owns 179,390 shares of the biopharmaceutical company’s stock valued at $1,823,000 after purchasing an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 68.20% of the company’s stock.
XENE has been the topic of several recent research reports. Guggenheim initiated coverage on Xenon Pharmaceuticals in a research note on Friday, September 20th. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Investment Research downgraded Xenon Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $9.25 price target on the stock. in a research note on Saturday. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $17.42.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
See Also: How Do Mutual Funds Work?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.